Royalty Pharma plc Class A Ordinary Shares (RPRX)
Stock · NASDAQ · Health Care
$60.85as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$48.9
Industry
Biotechnology: Pharmaceutical Preparations
Fundamentals
- Market cap
- $32.92B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
How Royalty Pharma plc Class A Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 11, 2026 · via SEC EDGAR / Finnhub
Royalty Pharma plc Class A Ordinary Shares Competitors
Chosen by industry and closest market cap.
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.85▼ 1.73%Market cap $32.92BP/E —
- ZTSZoetis Inc. Class A Common Stock$77.36▲ 3.12%Market cap $32.32BP/E 11.54$71$156.49
- ONCBeOne Medicines Ltd. American Depositary Shares$366.79▼ 1.53%Market cap $34.88BP/E 88.12$205.51$346
- ROIVRoivant Sciences Ltd. Common Shares$34.71▼ 7.64%Market cap $24.08BP/E —$11.85$37.97
- UTHRUnited Therapeutics Corporation Common Stock$515.57▼ 2.34%Market cap $21.92BP/E 17.03$302.19$609.35
- INSMInsmed Incorporated Common Stock$118.52▼ 2.36%Market cap $21.34BP/E —$90.39$212.75
- VTRSViatris Inc. Common Stock$16.34▼ 3.26%Market cap $20.53BP/E —$9.43$18.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.92B | — | $60.85 | ▼ 1.73% | |
| ZTS Zoetis Inc. Class A Common Stock | $32.32B | 11.54 | $77.36 | ▲ 3.12% | $71$156.49 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $34.88B | 88.12 | $366.79 | ▼ 1.53% | $205.51$346 |
| ROIV Roivant Sciences Ltd. Common Shares | $24.08B | — | $34.71 | ▼ 7.64% | $11.85$37.97 |
| UTHR United Therapeutics Corporation Common Stock | $21.92B | 17.03 | $515.57 | ▼ 2.34% | $302.19$609.35 |
| INSM Insmed Incorporated Common Stock | $21.34B | — | $118.52 | ▼ 2.36% | $90.39$212.75 |
| VTRS Viatris Inc. Common Stock | $20.53B | — | $16.34 | ▼ 3.26% | $9.43$18.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much TodayBenzinga · 8/21/2026
- Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 YearsBenzinga · 8/14/2026
- Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?Yahoo · 8/13/2026
- Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for InvestorsYahoo · 8/13/2026
- Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder DrugBenzinga · 8/13/2026
- Royalty Pharma (NASDAQ:RPRX) Hits Perfect Technical Rating with Breakout SetupChartMill · 8/13/2026
- Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year RunYahoo · 8/13/2026
- Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value DebateYahoo · 8/12/2026
Insider Activity
Insider Actions →Acquired
95.5K
Disposed
349.7K
- Marshall Urist · August 7, 2026 · Gift3.0K
- Terrance P. Coyne · August 7, 2026 · Gift18.5K
- Pablo G. Legorreta · August 7, 2026 · Gift30.0K
- Marshall Urist · August 5, 2026 · Grant8.3K
- Terrance P. Coyne · August 5, 2026 · Grant11.0K
- Christopher Hite · August 5, 2026 · Grant11.0K
- Pablo G. Legorreta · August 5, 2026 · Grant65.2K
- Marshall Urist · July 1, 2026 · Sale9.1K @ $55.88
- Christopher Hite · June 30, 2026 · Sale600 @ $57.09
- Christopher Hite · June 30, 2026 · Sale29.4K @ $56.44
- Christopher Hite · June 30, 2026 · Sale2.6K @ $57.1
- Christopher Hite · June 30, 2026 · Sale97.4K @ $56.5
- Marshall Urist · June 24, 2026 · Sale9.1K @ $55.18
- Christopher Hite · June 23, 2026 · Sale117.6K @ $54.47
- Christopher Hite · June 23, 2026 · Sale32.4K @ $54.11
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
Royalty Pharma: Recent Coverage Highlights Execution and Valuation Gap. Two recent Seeking Alpha articles focus on Royalty Pharma, pointing to strong execution, raised guidance, and the view that the market is underpricing the stock. Both pieces frame RPRX as a steady compounder rather than a fast-growing name, with a potential re-rating still on the table. The average analyst price target of $64.75 sits well above the current upper end of the 52-week range at $61.80, which helps put that re-rating discussion in context. No new company-issued catalysts were reported in the data provided.